HLA 2-3 antigen-mismatched stem cell transplantation for refracotry hematologic malignancies

HLA 2-3 antigen-mismatched stem cell transplantation for refracotry hematologic malignancies - Haploidentical stem cell transplantation for hematologic malignancies

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000011985

Enrollment

Registered

2013-10-10

Start date

2013-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

refractory hematologic malignancies

Interventions

fludarabine 30mg/m2 day -11,-10,-9,-8,-7,-6 melphalan 70mg/m2 day -7,-6 (cytarabine 2g/m2 day -11,-10,-9,-8) TBI 3Gy day -5 ATG 0.5mg/kg day -3 ATG 1mg/kg day -2,-1

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1) Relapse after allogeneic transplantation 2) Lack an avavilable HLA identical or 1 antigen-mismatched related or unrelated donor

Exclusion criteria

Exclusion criteria: 1) With uncontrol diabetes 2) With uncontrol hypertension 3) With active cancer 4) Positive of HBs Ag or HBe Ag 5) Positive of HIV Ab

Design outcomes

Primary

Measure	Time frame
Survival rate at 100 days after transplantation	—

Countries

Japan

Contacts

Public ContactShingo Yano

Jikei Universtiy Hospital Clinical Oncology and Hematology

yano@jikei.ac.jp03-3433-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026